Literature DB >> 12583819

Clinical effectiveness and cost-consequences of selective serotonin reuptake inhibitors in the treatment of sex offenders.

Y Adi1, D Ashcroft, K Browne, A Beech, A Fry-Smith, C Hyde.   

Abstract

Mesh:

Substances:

Year:  2002        PMID: 12583819

Source DB:  PubMed          Journal:  Health Technol Assess        ISSN: 1366-5278            Impact factor:   4.014


× No keyword cloud information.
  7 in total

1.  "We cut and drink blood when we have sex. Do we have a problem?" a case report of atypical antipsychotic-treated paraphilia.

Authors:  Roopa Sethi; Sachinder Vasudeva; Ashwini Saxena; Anita S Kablinger
Journal:  Prim Care Companion CNS Disord       Date:  2013

2.  Pharmacological interventions for those who have sexually offended or are at risk of offending.

Authors:  Omer Khan; Michael Ferriter; Nick Huband; Nadja Smailagic
Journal:  Cochrane Database Syst Rev       Date:  2009

Review 3.  Pharmacological interventions for those who have sexually offended or are at risk of offending.

Authors:  Omer Khan; Michael Ferriter; Nick Huband; Melanie J Powney; Jane A Dennis; Conor Duggan
Journal:  Cochrane Database Syst Rev       Date:  2015-02-18

Review 4.  Current concepts in the pharmacotherapy of paraphilias.

Authors:  Frederico D Garcia; Florence Thibaut
Journal:  Drugs       Date:  2011-04-16       Impact factor: 9.546

Review 5.  The Biological Treatment of Paraphilic Disorders: an Updated Review.

Authors:  Brian J Holoyda; Denise C Kellaher
Journal:  Curr Psychiatry Rep       Date:  2016-02       Impact factor: 5.285

Review 6.  Pharmacologic treatment of sex offenders with paraphilic disorder.

Authors:  Frederico Duarte Garcia; Heloise Garcia Delavenne; Alessandra de Fátima Almeida Assumpção; Florence Thibaut
Journal:  Curr Psychiatry Rep       Date:  2013-05       Impact factor: 5.285

7.  The use of cyproterone acetate in a forensic psychiatric cohort of male sex offenders and its associations with sexual activity and sexual functioning.

Authors:  Gian Lippi; Paul J van Staden
Journal:  S Afr J Psychiatr       Date:  2017-03-10       Impact factor: 1.550

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.